.jpg)
Aravax Appoints Dr Adrian Parry as Director of CMC as it Continues to Build Phase 3 Development Capabilities
Melbourne, Australia and Oxford, UK– 23 June 2025, a clinical-stage biotechnology company developing next-generation, disease-modifying...
Jun 23
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
Melbourne, Australia and Oxford, UK– 2 June 2025, Aravax, a clinical-stage biotechnology company developing next-generation,...
Jun 2